CN110753559A - 用于纤毛病的基因治疗 - Google Patents

用于纤毛病的基因治疗 Download PDF

Info

Publication number
CN110753559A
CN110753559A CN201880029421.3A CN201880029421A CN110753559A CN 110753559 A CN110753559 A CN 110753559A CN 201880029421 A CN201880029421 A CN 201880029421A CN 110753559 A CN110753559 A CN 110753559A
Authority
CN
China
Prior art keywords
vector
seq
gene
bbs1
ciliopathic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880029421.3A
Other languages
English (en)
Chinese (zh)
Inventor
菲利普·贝亚勒
维克托·赫南德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ucl Commercial Co Ltd
Original Assignee
Ucl Commercial Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Commercial Co Ltd filed Critical Ucl Commercial Co Ltd
Publication of CN110753559A publication Critical patent/CN110753559A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880029421.3A 2017-05-05 2018-05-04 用于纤毛病的基因治疗 Pending CN110753559A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1707212.5A GB201707212D0 (en) 2017-05-05 2017-05-05 Gene therapy for ciliopathies
GB1707212.5 2017-05-05
PCT/GB2018/051219 WO2018203092A1 (en) 2017-05-05 2018-05-04 Gene therapy for ciliopathies

Publications (1)

Publication Number Publication Date
CN110753559A true CN110753559A (zh) 2020-02-04

Family

ID=59065740

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880029421.3A Pending CN110753559A (zh) 2017-05-05 2018-05-04 用于纤毛病的基因治疗

Country Status (8)

Country Link
US (2) US12171794B2 (https=)
EP (1) EP3628011A1 (https=)
JP (2) JP7759174B2 (https=)
CN (1) CN110753559A (https=)
AU (1) AU2018262427B2 (https=)
CA (1) CA3060187A1 (https=)
GB (1) GB201707212D0 (https=)
WO (1) WO2018203092A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116042719A (zh) * 2022-12-28 2023-05-02 蓝图生物医药(广州)有限公司 一种重组腺相关病毒载体及其应用
US12171794B2 (en) 2017-05-05 2024-12-24 Ucl Business Ltd Gene therapy for ciliopathies

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118949075A (zh) * 2019-02-14 2024-11-15 埃泽瑞斯公司 纤毛疾病的治疗
KR20220083714A (ko) * 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
GB202005641D0 (en) * 2020-04-17 2020-06-03 Ucl Business Plc Gene therapy for bardet-biedl syndrome
WO2025049923A2 (en) * 2023-08-31 2025-03-06 The Board Of Trustees Of The Leland Stanford Junior University Novel treatments of ciliopathies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101094A2 (en) * 2006-02-23 2007-09-07 The Johns Hopkins University Bbs10 related diagnostic methods and reagents for bardet-biedl syndrome
US20130158104A1 (en) * 2010-06-10 2013-06-20 Laboratorios Del Dr Esteve S.A Vectors and sequences for the treatment of diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962788B2 (en) 2002-05-30 2005-11-08 University Of Iowa Research Foundation Identification of a gene causing the most common form of bardet-biedl syndrome and uses thereof
ES2697249T3 (es) * 2013-03-11 2019-01-22 Fond Telethon miR-204 y miR-211 y usos de los mismos
GB201707212D0 (en) 2017-05-05 2017-06-21 Ucl Business Plc Gene therapy for ciliopathies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101094A2 (en) * 2006-02-23 2007-09-07 The Johns Hopkins University Bbs10 related diagnostic methods and reagents for bardet-biedl syndrome
US20130158104A1 (en) * 2010-06-10 2013-06-20 Laboratorios Del Dr Esteve S.A Vectors and sequences for the treatment of diseases
JP2013531490A (ja) * 2010-06-10 2013-08-08 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 疾患の治療のためのベクター及び配列

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COREY L. WILLIAMS等: "Gene Therapeutic Reversal of Peripheral Olfactory Impairment in Bardet-Biedl Syndrome", MOL THER., vol. 25, no. 4, pages 904, XP055489651, DOI: 10.1016/j.ymthe.2017.02.006 *
SEONGJIN SEO等: "Subretinal Gene Therapy of Mice With Bardet-Biedl Syndrome Type 1", INVEST OPHTHALMOL VIS SCI., vol. 54, no. 9, pages 1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12171794B2 (en) 2017-05-05 2024-12-24 Ucl Business Ltd Gene therapy for ciliopathies
CN116042719A (zh) * 2022-12-28 2023-05-02 蓝图生物医药(广州)有限公司 一种重组腺相关病毒载体及其应用
CN116042719B (zh) * 2022-12-28 2025-11-11 蓝图生物医药(广州)有限公司 一种重组腺相关病毒载体及其应用

Also Published As

Publication number Publication date
GB201707212D0 (en) 2017-06-21
AU2018262427B2 (en) 2024-02-29
EP3628011A1 (en) 2020-04-01
US20250057899A1 (en) 2025-02-20
CA3060187A1 (en) 2018-11-08
JP2025120285A (ja) 2025-08-15
AU2018262427A1 (en) 2019-11-14
US20200069753A1 (en) 2020-03-05
JP7759174B2 (ja) 2025-10-23
JP2020518269A (ja) 2020-06-25
US12171794B2 (en) 2024-12-24
WO2018203092A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
US20250057899A1 (en) Gene therapy for ciliopathies
US20220265861A1 (en) Adeno-associated viral vectors useful in treatment of spinal muscular atropy
CN105408352B (zh) 通过双重aav载体有效递送大基因
TWI902656B (zh) 變體ＲＮＡｉ
US20110117058A1 (en) Method of treating genetic disorders
US20190343920A1 (en) Aav-mediated gene therapy for nphp5 lca-ciliopathy
CN107881198A (zh) 用于无脉络膜的基因疗法的aav载体
US10849991B2 (en) Gene therapy for the treatment of a disease of retinal cone cells
JP2022531809A (ja) ＡＴＰａｓｅ媒介性疾患の処置のための組成物および方法
BR112020010977A2 (pt) terapia de gene para mucopolissacaridose iiib
CN116134134A (zh) 用于治疗c9orf72相关疾病的三功能腺伴随病毒(aav)载体
US20230220420A1 (en) Gene therapy for bardet-biedl syndrome
WO2023231778A1 (zh) 用于治疗粘多糖贮积症iiia型的转基因表达盒
US11793887B2 (en) Gene therapy for treating peroxisomal disorders
US20220370638A1 (en) Compositions and methods for treatment of maple syrup urine disease
CN121057823A (zh) 体内修饰神经元以治疗和/或预防肌萎缩性侧索硬化(als)的方法
CN116670291A (zh) 用于神经退行性疾病的基因疗法
WO2025106562A1 (en) Mecp2 trans-splicing molecules
JP2024515612A (ja) 球脊髄性筋萎縮症（ｓｂｍａ）の治療に有用な組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination